Background: Hepatocellular carcinoma (HCC) is the most common and aggressive type of malignant liver tumor. HCC progression depends significantly on its vascularization and formation of new blood vessels. Vascular endothelial growth factor A (VEGFA) is a crucial regulator of tumor vascularization and components of VEGF-induced cell signaling pathways are important targets of therapeutical drugs that demonstrated the highest efficiency in case of advanced HCC (sorafenib and regorafenib). VEGFA is expressed as a set of isoforms with different functional properties, thus VEGFA isoform expression pattern may affect tumor sensitivity to anti-angiogenic drugs. However, information about VEGFA isoforms expression in HCC is still incomplete and contradictory. The present study aims to quantitatively investigate VEGFA isoform expression aberrations in HCC tissue. Methods: A total of 50 pairs of HCC and non-tumor tissue samples were used to evaluate the VEGFA isoform spectrum using RT-PCR and quantitatively estimate changes in isoform expression using RT-qPCR. Correlations between these changes and tumor clinicopathological characteristics were analyzed. Results: We identified VEGFA-189, VEGFA-165, and VEGFA-121 as predominant isoforms in liver tissue. Anti-angiogenic VEGFA-xxxb variants constituted no more than 5% of all mature VEGFA transcripts detected and their expression was not changed significantly in HCC tissue. We demonstrated for the first time that the least active variant VEGFA-189 is frequently repressed in HCC (p < 0.001), while no uniform changes were detected for potent angiogenesis stimulators VEGFA-165 and VEGFA-121. Isoform balance in HCC shifts from VEGFA-189 towards VEGFA-165 or VEGFA-121 in the majority of cases (p < 0.001). Changes in fractions, but not expression levels, of VEGFA-189 (decrease) and VEGFA-121 (increase) correlated with advanced Tumor-Node-Metastasis (TNM) and Barcelona Clinic Liver Cancer (BCLC) tumor stages (p < 0.05), VEGFA-189 fraction reduction was also associated with poor tumor differentiation (p < 0.05). Discussion: A distinct shift in VEGFA isoform balance towards more pro-angiogenic variants occurs in HCC tissue and may modulate overall impact of VEGFA signaling. We suppose that the ratio between VEGFA isoforms is an important parameter governing HCC angiogenesis that may affect HCC progression and be used for optimizing the strategy of HCC therapy by predicting the response to anti-angiogenic drugs.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide and the second leading cause of death among all cancer types. Deregulation of the networks of tissue-specific transcription factors (TFs) observed in HCC leads to profound changes in the hepatic transcriptional program that facilitates tumor progression. In addition, recent reports suggest that substantial aberrations in the production of TF isoforms occur in HCC. In vitro experiments have identified distinct isoform-specific regulatory functions and related biological effects of liver-specific TFs that are implicated in carcinogenesis, which may be relevant for tumor progression and clinical outcome. This study reviews available data on the expression of isoforms of liver-specific and ubiquitous TFs in the liver and HCC and their effects, including HNF4α, C/EBPs, p73 and TCF7L2, and indicates that assessment of the ratio of isoforms and targeting specific TF variants may be beneficial for the prognosis and treatment of HCC.
Аннотация Фиброламеллярная карцинома (ФлК) описана в 1956 г. как отдельный подтип гепатоцеллюлярного рака (ГЦР), диагностируемый у молодых пациентов, не имеющих хронических заболеваний печени. Морфологически ФлК характеризуется как ГЦР с крупными клетками, большими ядрами и наличием в строме ламеллярных коллагеновых волокон, образующих разветвленную сеть. Механизмы, определяющие развитие ФлК при отсутствии значимых факторов риска, долгое время оставались неизвестными. Высокопроизводительные методы исследования транскриптома позволили описать уникальный профиль экспрессии генов при ФлК, определить основные сигнальные пути, активированные в опухолевых клетках, такие как mTOR, FGFR и EGFR сигнальные каскады, которые могут рассматриваться как потенциальные терапевтические мишени для лечения этого типа опухолей. При полнотранскриптомном анализе в подавляющем большинстве образцов ФлК был впервые выявлен химерный транскрипт DNAJB1-PRKACA, который образуется в результате слияния двух генов при делеции участка 19 хромосомы. Эта перестройка является драйверным событием для возникновения ФлК и определяет ускорение пролиферации, повышение клоногенного потенциала и увеличение популяции опухолевых стволовых клеток. Слитный транскрипт специфичен для ФлК и может быть выявлен рядом клинических лабораторных методов, что открывает возможность для его использования в качестве маркера для дифференциальной диагностики этого типа опухолей. Поскольку слитный белок DNAJB1-PRKACA обладает киназной активностью, он рассматривается как перспективная мишень для разработки таргетных препаратов, способных ингибировать эту функцию. Анализ транскриптомных нарушений в ФлК позволил описать прогностическую сигнатуру из 8 генов, высокий уровень экспрессии которых коррелирует с плохой выживаемостью пациентов после хирургического лечения. В представленном обзоре суммированы современные сведения о молекулярном патогенезе ФлК и открывающихся на их основе возможностях для диагностики и разработки новых схем терапии.
15 December 2018 in Advances in molecular oncology
Proteins of the superfamily of small guanosine triphosphate hydrolase (GTPase) perform various functions: from the control of cell proliferation to the regulation of vesicular transport. The superfamily of small GTPase Ras includes more than 150 proteins, devided to 5 major families (Arf, Ran, Rho, Ras and Rab), and plays an important role in carcinogenesis. Compared to the other families, the Rab family was investigated by relatively small number studies, which does not equally reflect their role in malignant transformation processes. In our review we have focused on both the subfamily Rab3 and its poorly investigated member Rab3B. Recent findings allow to consider Rab3B not only as a promising diagnostic or prognostic marker for several types of neoplasms, but also is a potential target for antitumor therapy. Our analysis of publicly available transcriptional databases revealed that kidney, lung and liver cancer patients with low Rab3B gene expression demonstrate a better overall five-year survival.
15 December 2019 in Advances in molecular oncology
Background. Over 600,000 people die from hepatocellular carcinoma (HCC) each year worldwide. The disease is often detected at advanced stages and in many cases is not curable. Early diagnostic and monitoring of HCC recurrences remains a substantial problem in clinical oncology. That determines the need for a search for highly sensitive and specific biomarkers for the non-invasive of HCC diagnostics. The objective of the study. Identification of the hypermethylated locus in the promoter region of the septin 9 (Sept9) gene based on the annotated methylomes from the public databases. Experimental validation of methylation on a pilot panel of paired clinical samples of patients with HCC, as well as tissue samples from patients with benign liver tumors and lymphocytes from healthy donors. Materials and methods. To analyze the methyl data, samples of HCC from TCGA, hepatocellular adenoma from GEO (Gene Expression Omnibus) depository, peripheral blood cells and tissues of healthy donors from Methbank were used. Experimental validation of methylation levels of the identified site was carried out on a pilot panel of clinical samples by bisulphite pyrosequencing using PyroMark Q24.Results. Based on the analysis of methylome data, we selected cg20275528 site, which is characterized by high level of methylation in HCC tissues and minimal levels of methylation in non-tumor liver tissue, hepatocellular adenoma and peripheral blood of healthy donors. Experimental testing on a pilot panel of clinical specimens showed that the level of marker site methylation in HCC (42 % median) is significantly higher than in non-tumor liver tissues (3 % median) and benign neoplasms (1.5 % median) and exceeds the threshold value in HCC compared to paired samples of adjacent non-tumor liver tissue in 20 out of 30 studied cases (66.6 %). The general possibility for cg20275528 methylation detection in circulating DNA of plasma in HCC patients was shown.Conclusion. The obtained results indicate that the approach to the detection and experimental verification of diagnostically significant markers developed and tested in this study can be used to identify new differentially methylated sites and to establish new approaches for non-invasive HCC diagnosis.